Chapter
Gene expression profiling
Treatment-related prognostic factors
Prognostic factors at relapse
Prognostic factors at diagnosis
Peripheral T-cell lymphomas
Prognostic factors at diagnosis
Treatment-related prognostic factors
Prognostic factors at diagnosis
Treatment-related prognostic factors
Primary central nervous system lymphoma
Prognostic factors at diagnosis
Treatment-related prognostic factors
Prognostic factors at diagnosis
Related to tumor spread and tumor burden
Related to patient characteristics
Related to interaction of tumor and host
Treatment-related prognostic factors
Dose intensity and time to complete remission
Positron emission tomography (PET) using 18F-fluorodeoxyglucose (18FDG)
Prognostic factors at relapse
Chapter 4 Clinical trials in lymphoma
Evaluating treatment effect
Precision and error control
Randomized phase II trials
Chapter 5 Hodgkin lymphoma
Clinical presentation of Hodgkin lymphoma
Nodular lymphocyte-predominant Hodgkin lymphoma (nLPHL)
Classical Hodgkin lymphoma (cHL)
Lymphocyte-rich classical Hodgkin lymphoma (LR-cHL)
Mixed cellularity Hodgkin lymphoma (MC-HL)
Nodular sclerosis Hodgkin lymphoma (NS-HL)
Lymphocyte-depleted Hodgkin lymphoma (LD-HL)
Rare patterns of nodal infiltration
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma
Molecular pathology and cytogenetics
Diagnosis, staging, and risk stratification
Early-stage favorable Hodgkin lymphoma
Early-stage unfavorable disease
Advanced Hodgkin lymphoma
Treatment of primary progressive and relapsed Hodgkin lymphoma
Relapse after initial radiotherapy
Relapse after initial chemotherapy
Relapse after high-dose chemotherapy and autologous stem cell transplantation
Allogeneic stem cell transplantation
Anti-CD30 monoclonal antibodies/immunotoxins
Protein-specific “small molecules”
Histone deacetylase inhibitors (HDAC inhibitors)
Targeting the microenvironment
Nodular lymphocyte-predominant Hodgkin lymphoma (NLP-HL)
Treatment of Hodgkin lymphoma in children and adolescents
Treatment-associated toxicity
Chapter 6 Follicular lymphoma
Molecular and cytogenetics
Treatment of early-stage disease
Treatment of advanced disease in asymptomatic patients
First line treatment of advanced disease in symptomatic patients
Conventional chemotherapy
Combined immunochemotherapy
Autologous stem cell transplant (ASCT) in first remission
Summary: first line treatment of advanced lymphoma
Management of relapsed follicular lymphoma
Summary of immunochemotherapy as second line treatment
High-dose therapy and autologous stem cell transplantation
Allogeneic stem cell transplantation in FL (allo-SCT)
Summary of allogeneic transplantation
High-grade transformation of FL
Summary of relapsed follicular lymphoma
Chapter 7 MALT and other marginal zone lymphomas
Extranodal marginal zone B-cell lymphoma (MALT lymphoma)
The molecular biology of MALT lymphomas
Diagnosis and staging of gastric MALT lymphoma
Staging procedures in non-gastric MALT lymphoma
Helicobacter pylori eradication in gastric MALT lymphoma
Anti-Helicobacter therapy in gastric diffuse large B-cell lymphoma
Post-treatment histologic evaluation
Factors predicting the lymphoma response to H. pylori eradication
Clinical and molecular follow-up
Management of H. pylori-negative or antibiotic-resistant cases
Management of non-gastric localizations
Immunoproliferative small intestinal disease (IPSID)
Primary splenic marginal zone lymphoma
Molecular pathogenesis of splenic MZL
Clinical course and management
Nodal marginal zone lymphoma
Chapter 8 Small lymphocytic lymphoma/chronic lymphocytic leukemia
B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia
B-cell prolymphocytic leukemia (B-PLL)
Molecular pathology and cytogenetics
Treatment of CLL by risk stratification
Chemotherapeutic approach
Factors defining the choice of therapy
Choice of first line therapy in CLL
Previously untreated patients without 17p deletion who are fit
Previously untreated patients without 17p deletion with significant comorbidity
Previously untreated patients with 17p deletion and/or p53 mutation
Monoclonal antibody therapy in CLL
Choice of therapy in relapsed CLL
Role of allogeneic stem cell transplantation in CLL
1. Interfering with the microenvironment and its interaction with the CLL cell
2. Targeting downstream signaling from the B-cell receptor
4. Cyclin-dependent kinase inhibition
5. Immune-mediated approaches
6. Novel monoclonal antibodies
Recommended therapeutic approaches in CLL
Chapter 9 Waldenström’s macroglobulinemia/lymphoplasmacytic lymphoma
Epidemiology and etiology
Nature of the clonal cell
Bone marrow microenvironment
Morbidity mediated by the effects of IgM
Cold agglutinin hemolytic anemia
Manifestations related to tissue infiltration by neoplastic cells
Laboratory investigations and findings
Hematological abnormalities
Biochemical investigations
Treatment of Waldenström’s macroglobulinemia
High-dose therapy and stem cell transplantation
Response criteria in Waldenström’s macroglobulinemia
Chapter 10 Mantle cell lymphoma
Phenotypic and molecular markers
Conventional chemotherapy
Monoclonal antibody and combined immunochemotherapy
Dose-intensified regimens
Sequential dose intensification and autologous transplantation
Rituximab maintenance therapy
Allogeneic stem cell transplantation
Management of relapsed disease
Novel therapeutic approaches
Chapter 11 Burkitt and lymphoblastic lymphoma: clinical therapy and outcome
Introduction and presentation
Precursor B-lymphoblastic lymphoma/ lymphoblastic leukemia
Precursor T-lymphoblastic lymphoma/lymphoblastic leukemia
Molecular pathology and cytogenetics
B-cell lymphoma, unclassified, with features intermediate between DLBCL and Burkitt lymphoma
Precursor B-lymphoblastic leukemia/lymphoma
Precursor T-lymphoblastic leukemia/lymphoma
Treatment principles of Burkitt lymphoma
Treatment of Burkitt lymphoma
Management of relapse in Burkitt lymphoma
HIV-associated Burkitt lymphoma
Treatment recommendations in Burkitt lyphoma
Treatment principles of lymphoblastic lymphoma
Treatment of lymphoblastic lymphoma
CNS treatment of lymphoblastic lymphoma
Management of relapse in lymphoblastic lymphoma
Treatment recommendations for lymphoblastic lymphoma
Supportive care of Burkitt and lymphoblastic lymphoma
Chapter 12 Therapy of diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma not otherwise specified (NOS)
T-cell/histiocyte-rich B-cell lymphoma (TCHRBCL)
Diffuse large B-cell lymphoma with expression of full length anaplastic lymphoma kinase (ALK)
Intravascular large B-cell lymphoma
Diffuse large B-cell lymphoma associated with inflammation
EBV-positive diffuse large B-cell lymphoma of the elderly
Mediastinal (thymic) large B-cell lymphoma
Molecular pathology and cytogenetics
Treatment of early-stage DLBCL
Primary extranodal disease
Early-stage DLBCL – conclusions
Treatment of advanced-stage DLBCL
Dose-intensified and dose-dense therapy
High-dose therapy and autologous stem cell transplantation as a component of first line therapy
Addition of rituximab to chemotherapy
Addition of other new agents to chemotherapy
Use of involved-field radiation therapy in advanced DLBCL
Advanced stage DLBCL – conclusions
Primary mediastinal (thymic) large B-cell lymphoma
Management of relapsed DLBCL
Second line therapy prior to ASCT
High-dose therapy and autologous stem cell transplantation
Allogeneic stem cell transplantation in DLBCL
Prognostic factors for relapsed DLBCL
Other treatment approaches for relapsed disease
Radiolabeled monoclonal antibodies
Relapsed DLBCL – conclusions
New therapeutic targets in DLBCL
Chapter 13 Central nervous system lymphomas
Conventional therapeutic strategies
Methotrexate and cytarabine
Combined chemoradiotherapy
Experimental therapeutic strategies
High-dose chemotherapy supported by autologous stem cell transplantation
Blood–brain barrier disruption
Particular clinical conditions
CNS involvement in HIV-related lymphomas
Prophylaxis against CNS relapse
Autologous transplantation
Allogeneic transplantation
Rare forms of CNS lymphoma
Chapter 14 T-cell non-Hodgkin lymphoma
Adult T-cell leukemia/lymphoma (ATL)
Molecular pathology and cytogenetics
Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS)
Molecular pathology and cytogenetics
Angioimmunoblastic T-cell lymphoma (AITL)
Molecular pathology and cytogenetics
Anaplastic large-cell lymphoma (ALCL), systemic type, ALK+ and ALK–
Lymphohistiocytic variant (10%)
Small-cell variant (5–10%)
Other morphological patterns
Molecular pathology and cytogenetics
Subcutaneous panniculitis-like T-cell lymphoma (SCPTL)
Cutaneous gamma delta (γδ) T-cell lymphoma (CGD-TCL)
Hepatosplenic T-cell lymphoma (HSTCL)
Molecular pathology and cytogenetics
Extranodal NK-/T-cell lymphoma, nasal and nasal-type
Molecular pathology and cytogenetics
Enteropathy-type intestinal T-cell lymphoma (EITCL)
Molecular pathology and cytogenetics
Autologous stem cell transplantation
Frontline consolidative therapy
Allogeneic stem cell transplantation
Emerging and novel therapies
Chapter 15 Primary cutaneous lymphoma
Primary cutaneous T-cell lymphomas (CTCL)
Pathology of MF and Sézary syndrome
Molecular pathology of cutaneous lymphomas
Phototherapy and photochemotherapy
Radiotherapy and total skin electron beam therapy
Extracorporeal photopheresis
Monoclonal antibody therapy
Histone deacetylase (HDAC) inhibitors
Bone marrow transplantation
MF clinicopathologic variants
Folliculotropic and syringotropic MF
Granulomatous variants of MF
CD30+ T-cell lymphoproliferative disorders of the skin
Primary cutaneous (anaplastic) CD30-positive large-cell lymphoma
Molecular pathology of CD30+ T-cell lymphoproliferative disorders of the skin (CD30+ LPD)
Subcutaneous panniculitis-like T-cell lymphoma
Primary cutaneous peripheral T-cell lymphoma (PTL), unspecified
Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma
Primary cutaneous CD4+ small-/medium-sized pleomorphic T-cell lymphoma
Primary cutaneous B-cell lymphomas
Primary cutaneous marginal zone B-cell lymphoma/immunocytoma
Primary follicle center-cell lymphoma
Primary cutaneous large B-cell lymphoma (leg type and cutaneous large B-cell lymphoma at other sites)
Chapter 16 Lymphoma in the immunosuppressed
Tumors following solid organ transplantation (PTLD)
T-cell post-transplant lymphoproliferative disorders
Lymphomas in patients with HIV infection
Diffuse large B-cell lymphoma
Primary effusion lymphoma (PEL)
Plasmablastic lymphoma (PBL)
Primary central nervous system lymphoma
Chapter 17 Atypical lymphoproliferative, histiocytic, and dendritic cell disorders
Benign lymphoproliferative disorders
Progressive transformation of germinal centers
Vascular transformation of sinuses
Inflammatory pseudotumor of lymph nodes
Langerhans cell histiocytosis
Interdigitating dendritic cell sarcoma
Follicular dendritic cell sarcoma
Hemophagocytic lymphohistiocytosis
Atypical lymphoproliferative disorders
Unicentric Castleman’s disease
Multicentric Castleman’s disease
Lymphomatoid granulomatosis
Lymphoma
：Pathology, Diagnosis, and Treatment
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.